Atomega launced in KR

Selected as a regional economy-leading company for the youth recruitment support project.

Establishment of Kuhnil Bio Pharm

Certified as an innovative workplace company.

Obtained approval of Rosumega for Europe and Mongolia

Approval of EU-GMP

Signed an export contract with S.P.A Corp., Italy (exporting indigenously developed Rosumega soft capsules for hyperlipidemia treatment).

KI1106 selected as a government-supporting project.

Signed an exclusive contract with Kitov Corp., Israel (for a complex for the treatment of osteoarthritis).

Completion of the 2nd GMP-based plant in Cheonan

Establishment of BrioPharma, our subsidiary

Launching of Rosumega (Rosuvastatin plus omega-3).

Signed the technical alliance with Neurim Corp., Israel (to introduce Slenyto which is under development as the world's first pediatric sleep disorder treatment).

Signed the technical alliance contract with Neurim Corp., Israel

(Launched Circadin, the first in Korea and the world's only sleep hormone-based treatment for insomnia)

Selected as an innovative pharmaceutical company.

Establishment of STH Pharm, our subsidiary.

Integration of the R&D Unit and the Head Office through relocation to Jeong-dong.

Relocation of the Head Office to Jeong-dong.

Secured the investment from TTY Corp., Taiwan.

Establishment of Ohsong Pharm, our subsidiary.

Signed a technical alliance with Emcure Corp., India.

Signed a technical alliance with TTY Biotech Corp., Taiwan.

Signed a technical alliance with BioSyntech Corp., USA.

Signed a technical alliance with YM Biosyntech Corp., Canada.

Signed a technical alliance with BioPro(Guilford) Corp., USA.

Signed a technical alliance with Regulon Corp., Greece.

Signed a technical alliance with Cubist Corp., USA.

Signed a Korean license agreement for Multiferon® with Viragen Corp., USA.

Signed a technical alliance with Novatis (Gerber) Corp., Switzerland.

Signed a technical alliance with Vita Corp. and Vinas Corp., Spain.

Signed a technical alliance with SMB Corp. and Ipr@d Corp., France.

Signed a technical alliance with Senju (Bronuck®) Corp., Japan.

Signed a technical alliance with Pronova (Omacor®) Corp., Norway.

Signed a technical alliance with King Pharmaceuticals Corp., USA.

Certified as KGMP (Excellent Pharmaceutical Manufacturing and Quality Control Standard) qualified company.

Signed a technical alliance with Bausch & Lom Corp., USA (for ophthalmic products including Ocubyte).

Establishment of Penmix Co., Ltd., a subsidiary specializied in penicillin production.

CEO Young-Joong Kim was inaugurated.

Signed a technical alliance with Tedec Meiji Corp., Spain.

Signed a technical alliance with Biocodex Corp., France (A new level of yeast intestinal agent Biople launched).

Changed the company name from Kuhnil Yakpum to Kuhnil Pharm.

Extension of the Kuhnil Central R&D Center.

Signed a technical alliance with Solco Basel AG Corp., Switzerland (for Solcosfrene, a treatment for menopause disorders).

Signed a technical alliance with Lek dd Ljubljana (Sandoz) Corp., Slovenia.

(Amocla, a broad spectrum antibiotic effective against resistant bacteria, launched)

Approval of the Kuhnil Central R&D Center(Jiksan-eup, Cheonan-si, Chungnam).

Signed a technical alliance with Schering-Plough Corp., USA.

Designated as a KGMP-qualified company (Jiksan-eup, Cheonan-si, Chungnam).

Signed a technical alliance with Parke-Davis Corp., USA.

Signed a technical alliance with Wyeth-Ayerst International Inc., USA (A arthritis treatment Lodine released).

Signed a technical alliance with Merrell Dow Corp., USA.

Signed a technical alliance with Merck Corp.

Establishment of Kuhnil Pharm. (in Busan).

CEO Yong-Ok Kim was inaugurated.